Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 | Petroleo Brasileiro SA- Petrobras | BUY $18.5 | ― | 0.00% | Reiterated | Positive Outlook for Petrobras: Strategic Growth and Strong Shareholder Returns Drive Buy Rating | |||
| KE Holdings Inc. Sponsored ADR Class A | BUY $28 | ― | -12.60% | Reiterated | Miranda Zhuang Reaffirms Buy Rating on KE Holdings Inc. Amid Promising Market Conditions and Strong Performance | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $50→$74 | ― | 0.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $30 | ― | 7.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $155 | ― | 11.30% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $25→$28 | ― | 2.80% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $180 | ― | 2.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $206 | ― | 13.20% | Upgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $570 | ― | 18.20% | Initiated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $350 | ― | 18.20% | Initiated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $250 | ― | 18.20% | Initiated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $220 | ― | 18.20% | Initiated | ||||
 | Texas Instruments | HOLD $215 | ― | -1.40% | Assigned | Cautious Outlook on Texas Instruments Amid Manufacturing Investments and Market Volatility | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $85 | ― | 18.20% | Initiated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $115→$83 | ― | 8.00% | Downgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $23 | ― | 18.20% | Initiated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $14 | ― | 18.20% | Initiated | ||||
| Zymeworks | HOLD $12 | ― | -18.50% | Reiterated | Zymeworks Hold Rating: Balancing FDA Milestones with Market Valuation and Future Risks | |||
| Replimune Group | BUY $17 | ― | -18.50% | Reiterated | Buy Recommendation for Replimune Group: Promising Developments and Clinical Results of RP1 Treatment | |||
| Rallybio | BUY $5 | ― | -16.70% | Reiterated | Rallybio's Promising Advances and Financial Projections Earn 'Buy' Rating from Analyst | |||
| Korro Bio | BUY $115 | ― | -16.70% | Reiterated | Mitchell Kapoor Reaffirms Buy Rating for Korro Bio Amid Promising Developments in KRRO-110 Treatment | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $50 | ― | 3.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $90→$98 | ― | 2.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $164 | ― | 4.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $180 | ― | 6.00% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $125 | ― | 4.70% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $29→$30 | ― | 4.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $127→$132 | ― | 5.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $320→$375 | ― | 1.70% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $181 | ― | 0.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $74→$83 | ― | 6.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $26→$28 | ― | 0.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $330→$369 | ― | 12.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $685→$730 | ― | 15.70% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $610 | ― | 18.20% | Initiated | ||||
| Amphastar Pharmaceuticals | BUY $55 | ― | 1.70% | Initiated | Amphastar initiated with an Equal Weight at Wells Fargo | |||
| Life Time Group Holdings | BUY $29 | ― | -17.80% | Initiated | Life Time Group initiated with an Outperform at Evercore ISI | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $205→$215 | ― | 11.40% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $24→$28 | ― | 32.70% | Reiterated | ||||
 | Innovid | HOLD | ― | -4.70% | Downgraded | Innovid downgraded to Hold from Buy at Needham | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $37→$44 | ― | 5.80% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $19 | ― | 8.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $32 | ― | 8.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $178 | ― | 5.70% | Reiterated | ||||
| Autodesk | BUY $350 | ― | 0.00% | Assigned | Analysts Have Conflicting Sentiments on These Technology Companies: Autodesk (NASDAQ: ADSK), NetApp (NASDAQ: NTAP) and Alkami Technology (NASDAQ: ALKT) | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $135 | ― | 24.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $140 | ― | 24.80% | Assigned | ||||
| Gap Inc | BUY $30 | ― | -1.40% | Assigned | Gap Inc's Strong Performance and Promising Outlook Justify Buy Rating | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $135 | ― | 15.90% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $30 | ― | 18.20% | Assigned |
Rows:
